NSW Pharmacy Trial expression of interest closes 15 November

NSW Pharmacy Trial expression of interest closes 15 November websize image

Pharmacists have limited time left to register their interest in their pharmacy taking part in the NSW Pharmacy Trial, with the expression of interest process scheduled to close at 5pm on 15 November 2023.

The trial aims to allow appropriately trained pharmacists to provide community access to important medications and treatments that are usually only available with a prescription. The trial currently allows trained pharmacists from participating pharmacies to:

  • provide treatment for uncomplicated urinary tract infections in eligible patients; and
  • provide a re-supply of an eligible patient’s oral contraceptive.

The dermatological phase of the NSW Pharmacy Trial will commence next year. Pharmacies that would like to participate in the dermatological phase and any other forthcoming trial iterations must be opted in for the UTI and Oral Contraceptive arms of the trial.

If your pharmacy is currently actively participating and has provided consent in the ongoing NSW Pharmacy Trial for UTI and Oral Contraception, no further action is necessary.

For those pharmacies not yet involved, please register your interest with NSW Health before the expression of interest process closes. Once you have registered your interest, your registration information will be passed on to the trial research team. Please be advised that eligibility conditions apply, and an expression of interest does not guarantee participation in the trial. View the Authority allowing participating pharmacists to supply medications (UTI) and the Authority allowing pharmacists to supply medications (oral contraceptive pill) for eligibility requirements to participate. The Authority extends only to pharmacies and pharmacists that are participating in the trial.

The PDL Professional Officers stress the importance that no service delivery is undertaken until the pharmacy consent form is signed for the respective trials, and the onboarding process is fully completed. This includes ensuring MedAdvisor activation, issuance of the QR code for e-consent and the completion of necessary training by participating pharmacists, along with the submission of signed pharmacist consent forms via DocuSign.

Information regarding coverage for the UTI and Oral Contraceptive arms of the trial has been communicated in the following PDL Practice Alerts:

Information regarding coverage for the dermatological phase and future trial iterations will be provided closer to the commencement of these services within the trial.

For immediate advice and incident support, call PDL on 1300 854 838 to speak with one of our Professional Officers. We are here to support our pharmacist members 24/7.